Gigabac 1 M IV/IM Inj Injection

About Gigabac 1 M IV/IM Inj Injection

Gigabac 1 M IV/IM Inj is made by Square Pharmaceuticals PLC. It is a vial of 1 MIU/vial injection containing the antibacterial medicine Colistimethate Sodium, given by healthcare professionals for certain bacterial infections.

What is Gigabac 1 M IV/IM Inj Injection?

Gigabac 1 M IV/IM Inj is an injection supplied by Square Pharmaceuticals PLC. Each vial contains 1 MIU/vial of Colistimethate Sodium, which belongs to a group of antibacterial preparations. It is used to treat some acute or chronic infections caused by certain gram-negative bacteria, and it is used in particular for infections caused by sensitive strains of Pseudomonas aeruginosa. It is not meant for infections caused by Proteus or Neisseria. Because it is a hospital-type injection, a doctor or nurse gives it. The doctor decides whether it suits a particular infection and how it should be given.

Uses of Gigabac 1 M IV/IM Inj

Gigabac 1 M IV/IM Inj is used for acute or chronic infections caused by sensitive strains of certain gram-negative bacilli. It is particularly used for infections caused by sensitive strains of Pseudomonas aeruginosa. It does not treat infections due to Proteus or Neisseria. Only a doctor can confirm whether the infection is of a type this medicine can address, and the doctor decides the dose and course.

How to use Gigabac 1 M IV/IM Inj

Gigabac 1 M IV/IM Inj comes as a vial containing 1 MIU/vial of Colistimethate Sodium and is given by intravenous or intramuscular injection. A doctor or trained healthcare professional prepares and administers it, so patients should not attempt to use it themselves. The doctor sets the dose, the schedule and how long treatment continues, including any change needed for kidney problems. Ask the doctor or pharmacist about storage before and after the vial is prepared.

Side effects of Gigabac 1 M IV/IM Inj

Reported side effects include stomach upset, tingling of the hands, feet or tongue, slurred speech, dizziness, vertigo, numbness or unusual sensation, generalised itching, hives and rash, and fever. Changes in kidney-related blood tests, reduced urine output, breathing difficulty and pauses in breathing have also been reported. Tell the doctor promptly about any of these, and seek urgent help for breathing problems or greatly reduced urine output.

Safety and precautions

Tell the doctor before treatment if there is a history of allergy to Colistimethate Sodium or any ingredient of the injection. This medicine is used with caution in people with impaired kidney function, and the doctor may adjust the dose accordingly. It is also used with caution in newborns, infants and children. There are no adequate and well-controlled studies in pregnant women, and it crosses the placental barrier in humans, so it is used in pregnancy only if the benefit justifies the risk. It is not known whether it passes into breast milk, so nursing mothers should ask the doctor first.

Frequently asked questions

What does the generic name Colistimethate Sodium mean?

Colistimethate Sodium is the generic name of the active substance in the vial. It is an antibacterial medicine that acts on the bacterial cell membrane. Gigabac is the brand name under which Square Pharmaceuticals PLC supplies this injection.

What is Gigabac 1 M IV/IM Inj used for and what kind of medicine is it?

It is an antibacterial injection used for some acute or chronic infections caused by sensitive gram-negative bacteria, particularly Pseudomonas aeruginosa. It is not for infections due to Proteus or Neisseria. A doctor decides whether it is suitable for the infection.

What side effects should I watch for, and when should I call the doctor?

Watch for stomach upset, tingling, slurred speech, dizziness, itching, rash or fever. Call the doctor promptly about these. Seek urgent help for breathing difficulty, pauses in breathing or greatly reduced urine output, as these need immediate medical attention.

Who should ask a doctor before this injection is used?

People with kidney problems, a history of allergy to the medicine, pregnant women and nursing mothers should speak to the doctor first. Parents of newborns, infants and children should also ask the doctor. The doctor decides the dose, course and any needed adjustment.

Indications

Colistimethate is indicated for the treatment of acute or chronic infections caused by sensitive strains of certain gram-negative bacilli. It is particularly indicated in the infection caused by sensitive strains of Pseudomonas aeruginosa. Colistimethate is not indicated for infections due to Proteus ... Read moreColistimethate is indicated for the treatment of acute or chronic infections caused by sensitive strains of certain gram-negative bacilli. It is particularly indicated in the infection caused by sensitive strains of Pseudomonas aeruginosa. Colistimethate is not indicated for infections due to Proteus or Neisseria. Colistimethate is very effective in the treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Pharmacology

Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.

Dosage & Administration

Maintenance dose: 9 MIU/day in 2-3 divided doses. In patients who are critically ill, a loading dose of 9 MIU should be administered.

Renal impairment patients: Dose adjustments in renal impairment patients are necessary. Dose reductions are recommended for patients with creatinine clearance < 50 ml/min. Twice daily dosing is recommended.
  • Creatinine clearance <50-30 ml/min: daily dose 5.5-7.5 MIU
  • Creatinine clearance <30-10 ml/min: daily dose 4.5-5.5 MIU
  • Creatinine clearance <10 ml/min: daily dose 3.5 MIU
Haemodialysis (HD) patients:
  • No-HD days: 2.25 MIU/day (2.2-2.3 MIU/day).
  • HD days: 3 MIU/day (Should be given after the HD session) Twice daily dosing is recommended.
Pediatric population: The dose should be based on lean body weight.
  • Children ≤40 kg: 75,000-150,000 IU/kg/day divided into 3 doses.
  • Children >40 kg: >150,000 IU/kg/day has been reported in children with cystic fibrosis.
Hepatic impairment patients: There are no data in patients with hepatic impairment. Caution is advised when administering colistimethate sodium in these patients.

Interaction

Colistimethate should not be given with certain antibiotics like- aminoglycosides and polymyxin due to report of interfere with the nerve transmission at the neuromuscular junction. It should not be given with muscle relaxants e.g., tubocurarine and other drugs including ether, succinylcholine, gallamine, decamethonium and sodium citrate. The concomitant use of Sodium Cephalothin and Colistimethate should be avoided.

Contraindications

The use of Colistimethate Sodium Parenteral is contraindicated for patients with a history of sensitivity to the drug or any of its components.

Side Effects

The following adverse reactions have been reported: gastrointestinal upset, tingling of extremities and tongue, slurred speech, dizziness, vertigo and paresthesia, generalized itching, urticaria and rash, fever, increased blood urea nitrogen (BUN), elevated creatinine and decreased creatinine clearance, respiratory distress and apnea, nephrotoxicity and decreased urine output.

Pregnancy & Lactation

There are no adequate and well-controlled studies about the use of Colistimethate in pregnant women. Since colistimethate is transferred across the placental barrier in humans, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Colistimethate is excreted in human breast milk. Therefore, caution should be exercised when administered to nursing women.

Precautions & Warnings

Colistimethate should be used with caution in patient with impaired renal function. When actual renal impairment is present, Colistimethate may be used, but the greatest caution should be exercised and the dosage should be reduced in proportion to the extent of the impairment. Colistimethate should be used with caution in neonates, infants and children.

Overdose Effects

Overdosage with colistimethate sodium can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. Overdosage with the drug can also cause acute renal failure, manifested as decreased urine output and increases in serum concentrations of B.U.N and creatinine. As in any case of overdose, Colistimethate Sodium therapy should be discontinued and general supportive measures should be utilized.

Storage Conditions

Before reconstitution: Store below 30°C. After reconstitution: Store at 2°C to 8°C (Do not freeze) and use within 24 hours.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.